Introduction {#sec1-0300060519847796}
============

Anti-HER2 molecular targeted agents are established for treating breast cancer,^[@bibr1-0300060519847796][@bibr2-0300060519847796]--[@bibr3-0300060519847796]^ gastric cancer,^[@bibr4-0300060519847796]^ and metastatic colorectal cancer^[@bibr5-0300060519847796]^ in patients with HER2 gene amplification (an increase in the copy number). A combination of two HER2-targeted therapies, such as trastuzumab and lapatinib, has also been demonstrated to have clinical efficacy in advanced HER2-positive metastatic breast cancers^[@bibr2-0300060519847796],[@bibr3-0300060519847796]^ and colorectal cancers.^[@bibr5-0300060519847796]^

Lapatinib (GW572016) is a selective inhibitor of epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase,^[@bibr6-0300060519847796]^ and trastuzumab is a humanized monoclonal antibody that targets the HER-2 extracellular domain.^[@bibr7-0300060519847796]^ The dual targeting of HER2-positive tumors using trastuzumab and lapatinib results from the primary and acquired resistance of these two drugs, their partly non-overlapping mechanisms of action, and the well characterized synergistic interaction between them in HER2 breast-cancer models. Clinically, trastuzumab primarily induces pro-apoptotic effects, while lapatinib inhibits proliferation.^[@bibr8-0300060519847796],[@bibr9-0300060519847796]^ Clinical evidence shows indirect support for dual HER2 blockade. In patients with refractory breast cancer who are treated with trastuzumab, lapatinib plus trastuzumab prolonged the progression-free survival compared with lapatinib alone. Konecny et al.^[@bibr10-0300060519847796]^ analyzed the combination of trastuzumab plus lapatinib, and they observed synergistic drug interactions in four HER-2-overexpressing breast cancer cell lines. Additionally, similar results were obtained in the study reported by Baselga et al.,^[@bibr11-0300060519847796]^ which suggested complementary mechanisms of action and synergistic anti-tumor activity for the monoclonal antibody in a model of breast cancer that overexpressed HER2. Xu et al.^[@bibr3-0300060519847796]^ conducted a systematic review and meta-analysis of randomized controlled trials (RCTs), and the results showed that lapatinib plus trastuzumab significantly prolonged the pathological complete response, overall survival, and event-free survival with tolerance in HER2-positive breast cancer patients. Moreover, the combination of trastuzumab and lapatinib was also effective and well tolerated in patients with HER2-positive metastatic colorectal cancer refractory disease.^[@bibr5-0300060519847796]^

Gallbladder carcinoma (GBC) is a rare and highly aggressive tumor. Early diagnosis is challenging, which results in a poor prognosis in patients who receive systemic therapy. However, combination therapy with trastuzumab and lapatinib has not been reported in patients with GBC. Here, we present the case of a patient with dual-targeted HER2 therapy including lapatinib that was used to treat advanced GBC with brain metastases.

Case presentation {#sec2-0300060519847796}
=================

On 4 January 2016, a 48-year-old Chinese female patient was admitted to the Shaoxing People's Hospital because of nausea, vomiting, dizziness, headache, crooked mouth, and slurred speech. Magnetic resonance imaging (MRI) showed multi-site metastatic brain tumors ([Figure 1a](#fig1-0300060519847796){ref-type="fig"}) and bilateral adrenal gland metastasis (data not shown). Chest computed tomography (CT) scans revealed multi-site metastatic lung tumors ([Figure 1b](#fig1-0300060519847796){ref-type="fig"}). This patient was diagnosed with GBC via cholecystectomy that was performed because of cholecystitis and gallstones in 2010 (pT3N0M0; TNM staging: IIB; Nevin staging: III) ([Figure 1e](#fig1-0300060519847796){ref-type="fig"}). Lung metastasis was found in 2014, and brain metastasis was detected in 2015. The patient's medical history is shown in [Figure 2](#fig2-0300060519847796){ref-type="fig"}.

![Dual-targeted therapy with trastuzumab and lapatinib were effective in advanced gallbladder carcinoma patients with multi-site brain and lung metastases.\
Magnetic resonance imaging showed the status of brain metastases before (a) and after (c) three cycles of dual-HER2 targeted therapy with trastuzumab and lapatinib. Chest computed tomography scans showed the status of lung metastasis before (b) and after (d) three cycles of dual HER2-targeted therapy with trastuzumab and lapatinib. (e) A biopsy identified that the gallbladder tumor was moderate-differentiated adenocarcinoma (hematoxylin and eosin staining; original magnification ×100). (f) A biopsy showed that the metastatic brain tumors were adenocarcinoma (hematoxylin and eosin staining; original magnification ×100).](10.1177_0300060519847796-fig1){#fig1-0300060519847796}

![Medical history, clinical interventions, and metastasis development.](10.1177_0300060519847796-fig2){#fig2-0300060519847796}

One month after admission, the patient underwent surgery to remove one of the largest metastatic tumors (longest diameter in the transverse plane, 38.96 mm) in the left frontal lobe. The biopsy showed that the metastatic tumor was adenocarcinoma ([Figure 1f](#fig1-0300060519847796){ref-type="fig"}). The patient was diagnosed with the GBC brain metastasis after a comprehensive review. Genetic profiling of 416 cancer-relevant genes was performed using targeted next generation sequencing (NGS; see Materials and Methods) to develop potential molecular therapeutic approaches. GBC primary tumor and brain metastatic tissues, as well as the circulating tumor DNA (ctDNA) in the blood were collected from the patient for genetic profiling. The sequencing results showed a significant increase in the HER2 copy number in the GBC primary tumor (8.6×), brain metastasis (14.6×), and ctDNA (2.5×) ([Table 1](#table1-0300060519847796){ref-type="table"}). Thus, dual-targeted therapy was initiated on 6 March, 2016 using trastuzumab (administered intravenously at an initial dose of 8 mg/kg, followed by subsequent doses of 6 mg/kg once per week for 3 weeks) and lapatinib (administered orally each day at a dose of 1000 mg per day in 21-day treatment cycles), based on previously published work in breast cancer^[@bibr2-0300060519847796],[@bibr3-0300060519847796]^ (i.e., one dose of trastuzumab each week and one dose of oral lapatinib each day). No concurrent chemotherapy was administrated.

###### 

Genetic alterations identified in samples before/after HER2-targeted therapy.

![](10.1177_0300060519847796-table1)

  Sample type                                        Sample ID      Genetic alterations identified   MAF (%)/Fold change (×)
  -------------------------------------------------- -------------- -------------------------------- -------------------------
  Before HER2-targeted therapy                                                                       
   ctDNA                                             P16020611144   TP53: p.K291X (c.A871T)          4%
                                                                    CDK12: amplification             2.87×
                                                                    ERBB2: amplification             2.48×
   FFPE sample of                                    F16020611145   TP53: p.K291X (c.A871T)          31%
    gallbladder tumor                                               CDK12: amplification             9.03×
                                                                    ERBB2: amplification             8.40×
   FFPE sample of                                    F16020611146   TP53: p.K291X (c.A871T)          72%
    brain tumor                                                     CDK12: amplification             11.28×
                                                                    ERBB2: amplification             14.60×
                                                                    RB1: Single-copy loss            0.53×
  After three cycles of anti-HER2 targeted therapy                                                   
   ctDNA                                             P16051918361   TP53: p.K291X (c.A871T)          0.5%
                                                                    CDK12: amplification             Not detected
                                                                    ERBB2: amplification             Not detected
                                                                    RB1: Single-copy loss            Not detected

MAF, mutant allele frequency; ctDNA, circulating tumor DNA; FFPE, formalin-fixed paraffin-embedded.

Three weeks after dual HER2 targeted therapy with trastuzumab and lapatinib, the follow-up chest and brain MRI revealed that the patient achieved a partial response in brain metastatic tumors ([Figure 1c](#fig1-0300060519847796){ref-type="fig"}) and lung metastatic tumors ([Figure 1d](#fig1-0300060519847796){ref-type="fig"}), after three cycles of treatment based on the Response Criteria Evaluation in Solid Tumors (RECIST) version 1.1. The MRI results showed that the metastatic tumors had shrunk. A concurrent blood sample was collected for genetic testing of ctDNA using targeted NGS. The HER2 copy numbers did not increase at this time ([Table 1](#table1-0300060519847796){ref-type="table"}), suggesting that the tumors were cleared after trastuzumab and lapatinib dual therapy. It was also accompanied by a carcinoembryonic antigen (CEA) response (CEA levels decreased from 4030 ng/mL to 660 ng/mL). The patient developed grade 3 adverse reactions including fatigue, skin rash, and increased bilirubin concentration, but no grade 4 or 5 adverse reactions were observed. In summary, dual-targeted therapy with trastuzumab and lapatinib offered a chemotherapy-free option and achieved tumor suppression with an acceptable safety profile for this patient with HER2 amplification in GBC.

Materials and methods {#sec3-0300060519847796}
=====================

Patient information {#sec4-0300060519847796}
-------------------

The patient provided written informed consent. The study was approved by the ethics committee at the institute and was performed in strict accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization and Good Clinical Practice guidelines.

Tumor assessment {#sec5-0300060519847796}
----------------

Tumor measurements were performed by a radiologist (ZXL) before treatment and were assessed every 2 months in accordance with RECIST (version 1.1). The patient was examined using a CT of the chest, abdomen, or pelvis, and MRI brain scans when clinically indicated in accordance with the protocol. All tumor measurements were reviewed by a radiologist (ZXL) who read the MRI or CT scans, and collected, stored, and interpreted the imaging results.

Adverse reaction assessment {#sec6-0300060519847796}
---------------------------

The patient's health was continuously monitored and graded in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Laboratory test assessments (hematology, serum chemistry, urine analysis, and tumor markers) were performed at baseline (day 1 of every cycle), and at the end of treatment. The left ventricular ejection fraction was examined at baseline (day 1 of every cycle) and at the end of treatment.

DNA extraction {#sec7-0300060519847796}
--------------

Formalin-fixed paraffin-embedded (FFPE) tissues were sectioned, and hematoxylin and eosin (H&E)-stained slides were reviewed by surgical pathologists (FL and AJS). Tumor tissue areas were dissected from ten serial sections (4 μm) guided by H&E slides as templates. The FFPE tissues were deparaffinized with xylene and genomic DNA was extracted using a QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA, USA). The concentration of DNA was determined using a Qubit dsDNA HS assay kit on the Qubit 3.0 (Life Technologies, Carlsbad, CA, USA), in strict accordance with the manufacturer's protocol. DNA (A260/280 and A260/230) was measured using the Nanodrop-2000 (Thermo Fisher Scientific, Waltham, MA, USA).

Whole blood (8 mL) was collected using EDTA blood collection tubes (BD Biosciences, San Jose, CA, USA) that were centrifuged within 2 hours at 1800 ×*g* for 10 minutes at ≥4°C to collect the plasma. ctDNA was extracted from plasma using a QIAamp circulating nucleic acid kit (Qiagen). The purified ctDNA was quantified using a Qubit dsDNA HS assay kit on the Qubit 3.0 Fluorometer (Life Technologies).

Library construction {#sec8-0300060519847796}
--------------------

The sequencing library was prepared using a KAPA Hyper Prep Kit (Kapa Biosystems, Boston, MA, USA), in accordance with the manufacturing protocol. Briefly, 1 μg genomic DNA sample was fragmented into 350 bp in an Adaptive Focused Acoustics (AFA) fiber snap-cap microTUBE using Covaris M220 (Covaris, Woburn, MA, USA) or 10--50 ng ctDNA underwent end repairing, A-tailing, adapter ligation, size selection, and finally PCR amplification. Library concentration was determined using a Qubit dsDNA HS assay kit on the Qubit 3.0 Fluorometer (Life Technologies).

Hybrid capture and ultra-deep next generation sequencing {#sec9-0300060519847796}
--------------------------------------------------------

The 5ʹ-biotinylated probe solution was used as capture probes, which targeted 416 cancer-related genes ([Table 2](#table2-0300060519847796){ref-type="table"}). The capture reaction was performed using the NimbleGen SeqCap EZ hybridization and Wash Kit (Roche) with 1 μg of pooled libraries, 5 μg of human Cot-1 DNA, 1 unit of adapter-specific blocker DNA, and the capture probes. The solution hybridization was performed for 16--18 hours at 65°C. The captured targets were selected by pulling down the biotinylated probe/target hybrids using streptavidin-coated magnetic beads, and the off-target library was removed by washing with wash buffer, followed by PCR amplification of the target-enriched libraries. Sequencing libraries were quantified by qPCR using the KAPA Library Quantification kit (KAPA Biosystems, Boston, MA, USA), sized on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA), and then deep-sequenced on an Illumina HiSeq 4000 using the PE150 kit (Illumina Inc., San Diego, CA, USA).

###### 

Gene targeted in hybridization capture.

![](10.1177_0300060519847796-table2)

  --------------- ------------------ --------------- --------------- ------------------ ---------- ----------
  ABCB1 (MDR1)    CDK4               ERBB4           HGF             MSH2               PTEN       STK11
  ABCC2 (MRP2)    CDK6               ERCC1           HNF1A           MSH3               PTPN11     STMN1
  ACTB            CDK8               ERCC2           HNF1B           MSH6               PTPN2      STX11
  ADH1B           CDKN1B             ERCC3           HRAS            MTHFR              PTPN6      STXBP2
  AIP             CDKN1C             ERCC4           ID3             MTOR               PTPRO      SUFU
  AKT1            CDKN2A             ERCC5           IDH1            MUTYH              QKI        SUZ12
  AKT2            CDKN2B             ESR1            IDH2            MYC                RAC1       SYN3
  AKT3            CDKN2C             ETV1            IGF1R           MYCL1              RAD21      TCN2
  ALDH2           CEBPA              ETV4            IGF2            MYCN               RAD50      TEK
  ALK             CEP57              EWSR1           IKBKE           MYD88              RAD51      TEKT4
  AMER1           CHD4               EXT1            IKZF1           MYNN               RAD51C     TERC
  AP3B1           CHEK1              EXT2            IKZF2           NBN                RAD51D     TERT
  APC             CHEK2              EZH2            IKZF3           NCSTN              RAF1       TET2
  AR              CKS1B              FANCA           IL13            NF1                RARA       TGFBR2
  ARAF            CREBBP             FANCB           IL7R            NF2                RASGEF1A   TLE1
  ARID1A          CRKL               FANCC           INPP4B          NFKBIA             RB1        TLE4
  ARID2           CROT               FANCD2          INPP5D          NKX2-1             RECQL4     TMEM127
  ARID5B          CSF1R              FANCE           IRF1            NOTCH1             RELN       TMPRSS2
  ASXL1           CSF3R              FANCF           IRF2            NOTCH2             RET        TNFAIP3
  ATM             CTCF               FANCG           IRF4            NPM1               RHBDF2     TNFRSF14
  ATR             CTLA4              FANCI           IRF8            NQO1               RHOA       TNFRSF17
  ATRX            CTNNB1             FANCL           JAK1            NRAS               RICTOR     TNFRSF19
  AURKA           CUX1               FANCM           JAK2            NRG1               RNF146     TOP1
  AURKB           CXCR4              FAT1            JAK3            NSD1               RNF43      TOP2A
  AXIN1           CYLD               FBXO11          JARID2          NT5C2              ROS1       TP53
  AXL             CYP19A1            FCGR2B          JUN             NTRK1              RPTOR      TP63
  B2M             CYP2B6\*6          FGF19           KDM2B           PAG1               RRM1       TPMT
  BAP1            CYP2C19\*2         FGFR1           KDM5A           PAK3               RTEL1      TRAF2
  BARD1           CYP2C9\*3          FGFR2           KDR (VEGFR2)    PALB2              RUNX1      TRAF3
  BCL2            CYP2D6\*3          FGFR3           KIF1B           PARK2              SBDS       TRAF5
  BCL2L1          CYP2D6\*4          FGFR4           KIT             PAX5               SDHA       TSC1
  BCL2L2          CYP2D6\*5          FH              KMT2B           PBRM1              SDHAF2     TSC2
  BCORL1          CYP2D6\*6          FIP1L1          KMT2C           PC                 SDHB       TSHR
  BCL2L11 (BIM)   CYP3A4\*4          FLCN            KRAS            PDCD1              SDHC       TTF1
  BLM             CYP3A5\*1          FLT1 (VEGFR1)   LEF1            PDCD1LG2 (PD-L2)   SDHD       TUBB3
  BMPR1A          CYP3A5\*3          FLT3            LMO1            PDGFRA             SERP2      TYMS
  BRAF            DAB2               FLT4 (VEGFR4)   LSP1            PDGFRB             SETBP1     TYR
  BRCA1           DAXX               GADD45B         LYN             PDK1               SETD2      U2AF1
  BRCA2           DDR2               GATA1           LYST            PHF6               SF3B1      UGT1A1
  BRD4            DDX1               GATA2           LZTR1           PHOX2B             SGK1       UNC13D
  BRIP1           DHFR               GATA3           MAP2K1 (MEK1)   PICK3R1            SH2D1A     VEGFA
  BTG2            DICER1             GATA4           MAP2K2 (MEK2)   PIK3C3             SLX4       VHL
  BTK             DIS3L2             GATA6           MAP2K4          PIK3CA             SMAD2      WISP3
  BTLA            DLG2               GNA11           MAP3K1          PIK3CD             SMAD3      WRN
  BUB1B           DMNT3A             GNA13           MCL1            PIK3R1             SMAD4      WT1
  c11orf30        DNM2               GNAQ            MDM2            PIK3R2             SMAD7      XIAP
  CALR            DOCK1              GNAS            MDM4            PLCE1              SMARCA4    XPA
  CBL             DOT1L              GPC3            MECOM           PLK1               SMARCB1    XPC
  CCND1           DPYD               GRIN2A          MED12           PMS1               SMC1A      XPO1
  CCNE1           DUSP2              GRM3            MEF2B           PMS2               SMC3       XRCC1
  CCT6B           EBF1               GSTM1           MEN1            POLD1              SMO        YAP1
  CD22            ECT2L              GSTP1           MET             POLD3              SOX2       ZAP70
  CD274 (PD-L1)   EED                GSTT1           MGMT            POLE               SPOP       ZBTB20
  CD58            EGFR               HBA1            MITF            POT1               SRC        ZNF217
  CD70            EGR1               HBA2            MLH1            PPP2R1A            SRSF2      ZNF703
  CDA             EP300              HBB             MLL             PRDM1              STAG2      ZRSR2
  CDC73           EPCAM              HDAC1           MLLT10          PRF1               STAT3      
  CDH1            EPHA3              HDAC2           MLPH            PRKAR1A            STAT5A     
  CDK10           **ERBB2 (HER2)**   HDAC4           MPL             PRKCI              STAT5B     
  CDK12           ERBB3              HDAC7           MRE11A          PTCH1              STIL       
  --------------- ------------------ --------------- --------------- ------------------ ---------- ----------

Sequence alignment and data processing {#sec10-0300060519847796}
--------------------------------------

Quality control was applied using Trimmomatic.^[@bibr12-0300060519847796]^ High quality reads were mapped to the human genome (hg19, GRCh37 Genome Reference Consortium Human Reference 37) using a modified Burrows-Wheeler Aligner (BWA) version 0.7.12^[@bibr13-0300060519847796]^ with BWA-MEM algorithm and default parameters. The Genome Analysis Toolkit^[@bibr14-0300060519847796]^ (GATK, version 3.4-0) was modified and used to locally realign the BAM files at intervals with insertion/deletion (indel) mismatches and to recalibrate the BAM file read base quality scores. Single nucleotide variants (SNVs) and short indels were identified using VarScan2 2.3.9^[@bibr15-0300060519847796]^ with a minimum variant allele frequency threshold set at 0.01 and a p-value threshold for calling variants set at 0.05 to generate variant call format (VCF) files. All SNVs/indels were annotated using ANNOVAR, and each SNV/indel was manually checked using the integrative genomics viewer (IGV).^[@bibr16-0300060519847796]^ Copy number variations (CNVs) were identified using ADTEx 1.0.4.^[@bibr17-0300060519847796]^ The analysis and data are presented as copy number changes in all Tables.

Discussion {#sec11-0300060519847796}
==========

Recent studies have identified a subset of patients who are undergoing treatment for advanced GBC with HER2 overexpression or amplification that could potentially benefit from HER2-targeted therapy.^[@bibr6-0300060519847796],[@bibr7-0300060519847796]^ Some studies previously reported the use of HER2-targeted treatment to treat HER2-positive gallbladder cancers. One case included a significant reduction in lung metastasis in patients with HER2-amplified metastatic cholangiocarcinoma that was treated with trastuzumab and paclitaxel.^[@bibr8-0300060519847796]^ Another study retrospectively reviewed GBC patients who received HER2-directed therapy with trastuzumab, lapatinib, or pertuzumab, and showed that HER2 blockage was a promising treatment strategy in HER2-positive GBC patients.^[@bibr7-0300060519847796]^ Most of those patients received a single HER2-targeted reagent combined with chemotherapy.

Clinical trials have demonstrated that lapatinib can be used as a therapeutic option for advanced HER2 alterations in cancers with brain metastasis.^[@bibr9-0300060519847796]^ Considering the multi-site brain and lung metastases of the GBC patients, we administrated dual-targeted HER2 therapy with trastuzumab and lapatinib and achieved PR after 4 months of treatment without concurrent chemotherapy. In summary, this is the first study to administer dual-targeted HER2 therapy including lapatinib to treat patients with advanced GBC with brain metastases. Patient follow-up and further multi-center clinical trials are necessary to investigate the long-term efficacy.

Conclusion {#sec12-0300060519847796}
==========

HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and used in combination with lapatinib, it can effectively target brain metastasis.
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